What’s the current market cap for Immatics stock?

Immatics (IMTX) has a market cap of $1.2bn as of June 17, 2026.

What is the P/E ratio for Immatics stock?

The price to earnings (P/E) ratio for Immatics (IMTX) stock is 0 as of June 17, 2026.

Does Immatics stock pay dividends?

No, Immatics (IMTX) stock does not pay dividends to its shareholders as of June 17, 2026.

When is the next Immatics dividend payment date?

Immatics (IMTX) stock does not pay dividends to its shareholders.

What is the beta indicator for Immatics?

Immatics (IMTX) has a beta rating of 1.3. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy Immatics stock | $IMTX Share Price

13:30

15:10

16:45

18:25

20:00

About Immatics

Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.

Ticker

$IMTX

Sector

Health

Primary listing

NASDAQ

Employees

678

Headquarters

Tübingen, Germany

Website

www.immatics.com

Immatics Metrics

BasicAdvanced

$1.2bn

-$1.99

1.30

What the Analysts think about Immatics

Analyst ratings (Buy, Hold, Sell) for Immatics stock.

Bulls say / Bears say

Cash and cash equivalents and other financial assets of $521.5 million (€453.6 million) as of March 31, 2026 provide Immatics with funding into 2028, reducing refinancing risk. (Nasdaq)

Pre-specified interim and final analyses from the Phase 3 SUPRAME trial of lead cell therapy anzu-cel (IMA203) are expected in 2026, keeping Immatics on track for a BLA submission in 1H 2027 and potential commercial launch in 2H 2027. (Nasdaq)

Updated Phase 1b data for second-generation PRAME cell therapy IMA203CD8 presented at ASCO 2026 showed a 63% ORR and 50% cORR in platinum-resistant ovarian and uterine cancers, with durable responses up to 12 months, supporting expansion across solid tumors. (Nasdaq)

Net loss widened to $66.5 million (€57.8 million) in Q1 2026 from a net profit of €39.9 million a year ago, as R&D expenses jumped to €59.2 million, underscoring high burn without offsetting revenue growth. (Nasdaq)

Collaboration revenue fell sharply to €7.6 million in Q1 2026 from €18.6 million in Q1 2025, highlighting a reduction in external funding support at a critical stage of pipeline advancement. (Nasdaq)

All of Immatics’s Q1 2026 revenue of €7.6 million was derived from collaboration agreements, with no product sales, leaving the company heavily reliant on partnerships and capital markets for funding. (Nasdaq)

Data summarised monthly by Lightyear AI. Last updated on 9 Jun 2026.

Immatics Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

Immatics Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $IMTX

Capital at risk

Market closed

Upcoming events

No upcoming events

Bulls say / Bears say

Cash and cash equivalents and other financial assets of $521.5 million (€453.6 million) as of March 31, 2026 provide Immatics with funding into 2028, reducing refinancing risk. (Nasdaq)

Data summarised monthly by Lightyear AI. Last updated on 9 Jun 2026.

About Immatics

Ticker

Employees

Immatics Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

What the Analysts think about Immatics

Analyst Ratings

Bulls say / Bears say

Immatics Financial Performance

Income Statement

Immatics Earnings Performance

Earnings per share (EPS)

Buy $IMTX

Upcoming events

No upcoming events

Lightyear

Legal

Work with us

Bulls say / Bears say

Immatics/$IMTX

About Immatics

Ticker

Employees

Immatics Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

What the Analysts think about Immatics

Analyst Ratings

Bulls say / Bears say

Immatics Financial Performance

Income Statement

Immatics Earnings Performance

Earnings per share (EPS)

Buy $IMTX

Upcoming events

No upcoming events

What’s the current market cap for Immatics stock?

What is the P/E ratio for Immatics stock?

Does Immatics stock pay dividends?

When is the next Immatics dividend payment date?

What is the beta indicator for Immatics?

Bulls say / Bears say